Human tissue kallikreins are fifteen homologous genes encoding for secreted serine proteases and residing tandemly on chromosome 19q13.4. These enzymes are highly expressed in a variety of tissues and participate in diverse physiological processes. Human tissue kallikreins were found to be associated with several malignancies, especially endocrine-related cancers, including prostate, ovarian, breast and testicular cancer. In testicular germ cell tumors, some tissue kallikrein genes, including KLK5, KLK10, KLK13 and KLK14, were found to be significantly down-regulated. Tissue-specific splice variant forms of some kallikreins have been identified in the testis. In this paper, the expression of KLK5, KLK10, KLK13 and KLK14 in testicular cancer and their possible roles during testicular cancer development, as well as their clinical applications are briefly reviewed.
Historically, kallikreins referred to a group of proteases that could release vasoactive peptides from high molecular weight precursors (1) . There are two categories of kallikrein enzymes: plasma kallikrein and tissue kallikrein. Plasma kallikrein is encoded by a single gene (KLKB1) residing on chromosome 4 (2). This enzyme is produced solely by liver cells and cleaves high molecular weight kininogen to release bradykinin (3) . Tissue kallikrein is now a generic term describing all serine proteases that tandemly locate on human chromosome 19q13.4 and share extensive homology at both the DNA and protein level (4) . This definition is not based on the enzymatic activities, but more on sequence homology and physical linkage. Initially, the human tissue kallikrein gene family was thought to include only three members: KLK1 (renal/ 225 pancreatic kallikrein), KLK2 (glandular kallikrein), and KLK3 (prostate specific antigen) (1) . During the past few years, another 12 new members were identified in the same locus (4) . These new kallikrein genes were given the names as KLK4 to KLK15. The encoded proteins were designated as hK4 to hK15 (5) .
LOCUS ORGANIZATION
The human tissue kallikrein gene locus spans about 340 kb of genomic sequence. The organization of the kallikrein genes in the locus is shown in Fig. 1 . The kallikreins reside tandemly in the locus without any other intervening genes. The testicular acid phosphatase (ACPT) gene and the SIGLEC-9 gene define to the 5ø and 3ø end of the locus, respectively. KLK2 and KLK3 are transcribed in the same direction, from centromere to telomere, whereas the rest of the kallikreins transcribe in the opposite direction.
TISSUE EXPRESSION AND HORMONAL REGULATION OF THE HUMAN TISSUE KALLIKREINS
Human tissue kallikreins were found to be expressed in a variety of tissues, such as the salivary glands, esophagus, tonsil and skin, determined by both RT-PCR (mRNA) and immunoassays (proteins). They are also highly expressed in endocrine-related tissues, including breast, ovary, testis and prostate (4) . Interestingly, the expression of most kallikreins is regulated by steroid hormones. KLK1 has been reported to be up-regulated by estrogen as demonstrated by its differential expression during the menstrual cycle (6) . KLK2 and KLK3 are well-known to be up-regulated by androgens and progestins in both cancer cell lines and animal models (7, 8) . Androgen response elements (AREs) within the KLK2 and KLK3 promoters that mediate the hormonal regulation have been identified (9) (10) (11) (12) . Although an estrogen response element (ERE) was also predicted to be present in the KLK1 gene promoter, it has not been functionally tested (13) . For the rest of the tissue kallikreins, to some extend, their expression is regulated by estrogen, androgen and progestin, based on studies performed in cancer cell lines (4). Considering the high expression level of the tissue kallikreins in sex organs, and their regulation by sex hormones, it is possible that the 226 tissue kallikreins are down-stream mediators of sex hormone action.
ENZYMATIC ACTIVITIES AND PHYSIOLOGICAL FUNCTIONS OF THE HUMAN TISSUE KALLIKREINS
Among all the tissue kallikreins, hK1 is the only one that has true kininogenase activity. It can cleave low molecular weight kininogen to release Lys-bradykinin, which binds to the G-protein coupled kinin receptor B to modulate a variety of physiological processes, such as regulation of blood flow, vascular permeability and Na π / water homeostasis (14) . hK2 and hK3 (also known as prostate specific antigen) are two tissue kallikreins that are predominantly expressed in the prostate. hK2 has been shown to have trypsin-like enzymatic activity and be able to activate hK3 (15) (16) (17) (18) . However, its exact physiological functions remain unknown. hK3 has chymotrypsin-like enzymatic activity and its major physiological function is to cleave seminogelin to liquefy semen clots (19, 20) . For the rest of the tissue kallikreins, their enzymatic activities have not been studied in detail so far. Preliminary experiments have shown that hK6, hK8 and hK11 have trypsin-like enzymatic activity (21-24), whereas, hK7's enzymatic activity is chymotrypsin-like (25, 26) . hK6 (also known as zyme/neurosin) is highly expressed in the brain. It is thought to be involved in the cleavage of amyloid precursor protein and thus, it could be implicated with Alzheimer's disease (27, 28) . hK7 (also known as human stratum corneum chymotryptic enzyme, HSCCE) was initially identified from a keratinocyte derivedlibrary (25) . In some studies, it has been shown that abundant expression of hK7 is restricted to the skin and hK7 appears to catalyze the degradation of intercellular cohesive structures in outermost cornified layer of the skin and contributes to the cell shedding process at the skin surface (25, 26) . The physiological substrates of hK8 (also known as neuropsin) remain unclear although some experiments have indicated that it can cleave fibronectin (23) . Through protein sequence homology comparison, hK4, hK5, hK10, hK12, hK13 and hK14 are predicted to have trypsin-like activity and hK9 and hK15 could possess chymotrypsin-like activity (4). However, these predicted enzymatic activities have not been experimentally tested and hence, their physiological substrates and functions are still not yet known.
HUMAN TISSUE KALLIKREINS AND CANCER
Human tissue kallikreins are secreted serine proteases, which can be detected in various biological fluids. During malignant transformation, the expression of tissue kallikreins could change. Therefore, they may have potential as biomarkers of various malignancies. hK2 and hK3 have applications mainly in prostate cancer. During prostate cancer development, the serum levels of both kallikreins are elevated (29) . Serum hK2, in combination with hK3, has value in the differential diagnosis between prostate cancer and benign prostatic hyperplasia (30) . Serum hK3 is the best prostate cancer biomarker discovered so far and has been widely used as a screening test and for prostate cancer monitoring. The expression of hK3 is actually down-regulated in aggressive prostate tumors (31, 32) . hK3 also has potential clinical utility in breast cancer. It has been reported that high levels of PSA in breast tumors predict favorable prognosis of breast cancer (33) . For the newly discovered tissue kallikreins, the malignancy that they are more closely associated with, is ovarian cancer (34, 35 expression and testicular cancer has been studied preliminarily. In contrast to their overexpression in ovarian cancer, the expression of these genes appears to be universally downregulated in testicular cancer. The expression level of the KLK5 gene was determined with quantitative RT-PCR technique. It was found that KLK5 is expressed by both normal and cancerous testicular tissues. However, in 93% of testicular cancer patients, KLK5 expression in the cancerous region was significantly (50%) lower than in the adjacent, histologically normal testicular tissues. Lower KLK5 expression was also more frequently observed in seminomas than in nonseminomas. Furthermore, low KLK5 expression seemed to be associated with aggressiveness of testicular tumors. In late stage (II/III) tumors and tumors with vascular/lymphatic invasion, KLK5 expression was lower than those with early stage (stage I) or tumors limited to the testis, respectively (50) .
The expression of KLK10 in normal testicular tissue has been investigated with immunohistochemistry. As Fig. 2 shows, germ cells, mainly spermatogonia, stain strongly for hK10 protein. A diffuse staining was also observed in Sertoli cells, especially in areas adjacent to spermatogonia, and in the basement membrane of seminiferous tubles. A weak reaction was 228 seen in Leydig cells. Also, with RT-PCR, the expression of KLK10 was investigated in normal and cancerous testicular tissues. CIS (carcinoma in situ) and Leydig cell tumors have nearly as high level of KLK10 expression as normal parachyma, whereas, seminoma and nonseminoma have very low or no expression of KLK10, compared to their adjacent normal counterparts. This observation was further confirmed with randomly selected normal and cancerous testicular tissues (51) . Immunohistochemical staining of hK10 protein in germ cell tumors verified that the malignant germ cells lacked hK10 staining, whereas, some well-differentiated epithelial components still retained strong hK10 staining (51) . These results indicate that normal germ cells express high levels of KLK10 but during germ cell malignant transformation, the expression of the KLK10 gene is down-regulated, which leads to low or no expression of hK10 protein in germ cell tumors.
The expression of KLK13 in testicular cancer was also investigated. KLK13 has seven splice variants, which originate by alternative splicing of exon 3. Among these splice variants, one (classic form) gives rise to the full-length prepro-hK13 protein. For the rest of the six splice variants, they are predicted to encode for truncated forms of hK13. The classic form and all the variant forms are expressed at the mRNA level, in normal testicular tissues. Interestingly, the expression of the variant forms is restricted to normal testicular tissue, while the classic form is widely expressed in many other normal tissues. In germ cell tumors, the classic form has similar expression level as in normal testicular tissues, however, all the variant forms become undetectable in tumors (52) .
Similarly to KLK5 and KLK10, KLK14 expression was also found to be lower in 70% of testicular tumors (53).
The physiological functions of kallikreins in testicular tissue are still not clear. KLK5, KLK10, KLK13 and KLK14 are all serine proteases with trypsin-like enzymatic activity (4). However, their physiological substrates in testicular tissues remain undetermined. In the testis, the differentiation of diploid spermatogonia into haploid spermatozoa involves successive rounds of mitotic and meiotic cell divisions and extensive morphological reconstruction. Proteolytic reactions leading to cell proliferation, apoptosis, differentiation and migration are crucial steps in the process of normal germ cell development. The kallikreins may participate in one or more of these proteolytic events. Alternatively, during spermatogenesis, communication between germ cells and Sertoli cells through specific soluble factors are essential (54) . It is possible that tissue kallikreins may be involved in the cleavage of these specific factors. During germ cell tumor development, the abnormal germ cell proliferation and differentiation may lead to down-regulation of the tissue kallikrein genes. In addition, given that multiple tissue kallikrein genes are expressed in the testicular tissue, it is possible that they are components of proteolytic cascade reactions as we proposed for ovarian cancer (34) .
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Some experimental evidence has suggested that KLK10 may function as a tumor suppressor gene. Overexpression of KLK10 can reduce tumor formation in nude mice and inhibit anchorage independent growth of breast cancer cell lines (55) . Furthermore, KLK10 expression is down-regulated in breast and prostate cancer cell lines as well as in breast tumors (48, 55) . It has been shown that this down-regulation is due to hypermethylation of the KLK10 gene itself (56) . The down-regulation of KLK10 in testicular cancer is in accord with the hypothetical tumor suppressor function of KLK10. Whether KLK10 and the other kallikrein genes are down-regulated in testicular cancer through the same mechanisms needs to be experimentally determined.
The down-regulation of kallikrein genes in testicular cancer is in sharp contrast to their overexpression in ovarian cancer (34 We are also limited by our methodology and the number of kallikreins which we have studied. We have antibodies for many of the kallikreins, and it would be interesting to detect KLK expression at the protein level by ICH comparing normal tissue, CIS and overt cancer.
Leendert Looijenga: Interestingly, you suggest that KLK 10 is a tumour suppressor gene.
Eleftherios Diamandis:
We must look at KLK 10 but also other genes. We have excellent monoclonal antibodies which react with numerous different kallikreins and these can be used on paraffin sections.
Anders Bjartell (Malmö, Sweden): Are some of the kallikreins rapidly degraded in tissue, be-233 cause they may be involved in a cascade reaction? This would cause difficulty in detecting them by IHC.
Kallikreins are involved in cascade reactions: many are trypsin-like proteases and act together activating different steps in the pathway, and many are degraded in the process. It is not always easy to demonstrate the tissue expression of these proteins, and sometimes we have to predict their presence. Some kallikreins are, therefore, silencing other members by their proteolytic enzymatic action. We need further experiments in order to build the pathways and to localise the genes. The mode of regulation, and more importantly the mode of expression, suggest that these genes are acting together as a group rather than single enzymes acting one at a time.
